EP1771203A4 - Inhibition of nf-kb - Google Patents

Inhibition of nf-kb

Info

Publication number
EP1771203A4
EP1771203A4 EP05791579A EP05791579A EP1771203A4 EP 1771203 A4 EP1771203 A4 EP 1771203A4 EP 05791579 A EP05791579 A EP 05791579A EP 05791579 A EP05791579 A EP 05791579A EP 1771203 A4 EP1771203 A4 EP 1771203A4
Authority
EP
European Patent Office
Prior art keywords
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05791579A
Other languages
German (de)
French (fr)
Other versions
EP1771203A2 (en
Inventor
Andrei V Gudkov
Katerina V Gurova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cleveland Clinic Foundation
Original Assignee
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation filed Critical Cleveland Clinic Foundation
Publication of EP1771203A2 publication Critical patent/EP1771203A2/en
Publication of EP1771203A4 publication Critical patent/EP1771203A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Transplantation (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
EP05791579A 2004-07-20 2005-07-20 Inhibition of nf-kb Withdrawn EP1771203A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58963704P 2004-07-20 2004-07-20
PCT/US2005/025884 WO2006012419A2 (en) 2004-07-20 2005-07-20 Inhibition of nf-kb

Publications (2)

Publication Number Publication Date
EP1771203A2 EP1771203A2 (en) 2007-04-11
EP1771203A4 true EP1771203A4 (en) 2010-06-02

Family

ID=35786698

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05791579A Withdrawn EP1771203A4 (en) 2004-07-20 2005-07-20 Inhibition of nf-kb

Country Status (4)

Country Link
EP (1) EP1771203A4 (en)
JP (3) JP2008507545A (en)
AU (1) AU2005267117C1 (en)
WO (1) WO2006012419A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090099191A1 (en) * 2006-02-02 2009-04-16 Gudkov Andrei V Inhibition of nf-kb
EA021331B1 (en) * 2008-05-20 2015-05-29 Общество С Ограниченной Ответственностью "Инкурон" Inducing cell death by inhibiting adaptive heat shock response
UA107652C2 (en) * 2008-10-06 2015-02-10 Incuron Llc Carbazole compounds and therapeutic uses of the compounds
GR1006794B (en) 2009-02-26 2010-06-04 Αλεξανδρος Βαμβακιδης The new sigma(σ)-receptor ligands with anti-apoptotic and/or pro-apoptotic properties over cellular biochemical mechanisms, with neuroprotective, anti-cancer, anti-metastatic and anti-(chronic) inflammatory action.
US20110060000A1 (en) * 2009-09-10 2011-03-10 Maurizio Grimaldi Acridine analogs in the treatment of gliomas
KR101812952B1 (en) * 2016-09-07 2017-12-28 부산대학교 산학협력단 Composition for preventing or treating refractory cancer comprising Quinacrine
CN115212209B (en) * 2021-04-19 2023-11-28 中国科学院分子细胞科学卓越创新中心 Antitumor drug with immunoadjuvant activity and capable of promoting immunotherapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007059482A2 (en) * 2005-11-14 2007-05-24 Cleveland Clinic Foundation Modulation of immune responses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001131066A (en) 1999-08-25 2001-05-15 Nippon Kayaku Co Ltd Apoptosis enhancer
JP4204980B2 (en) * 2002-03-07 2009-01-07 サムジン ファーマシューティカル カンパニー リミテッド 9-aminoacridine derivative and method for producing the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007059482A2 (en) * 2005-11-14 2007-05-24 Cleveland Clinic Foundation Modulation of immune responses

Also Published As

Publication number Publication date
JP2011219499A (en) 2011-11-04
EP1771203A2 (en) 2007-04-11
JP2008507545A (en) 2008-03-13
WO2006012419A2 (en) 2006-02-02
WO2006012419A3 (en) 2007-03-08
AU2005267117C1 (en) 2012-10-25
AU2005267117B2 (en) 2012-06-21
AU2005267117A1 (en) 2006-02-02
JP2014074056A (en) 2014-04-24

Similar Documents

Publication Publication Date Title
SI1802579T1 (en) Derivatives of 3-arylaminopyridine
HK1100930A1 (en) Inhibitors of iap iap
IL179854A0 (en) Inhibitors of iap
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en) PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
SG156674A1 (en) Asphaltene inhibition
IL179398A0 (en) Dpp-ib inhibitors
EP1756092A4 (en) Novel inhibitors of rho-kinases
EP1788874A4 (en) Salts of 5-azacytidine
AU304443S (en) Toilet
EP1771203A4 (en) Inhibition of nf-kb
GB0421355D0 (en) Inhibitors
AU303116S (en) Toilet
GB0421356D0 (en) Inhibitors
IL196187A0 (en) NF-kB INHIBITOR
GB0405228D0 (en) Bathing aid
GB0511809D0 (en) Toilet
GB2414745B (en) Euroblock - flood prevention specification
GB0404518D0 (en) Protection of sanitaryware
GB0410299D0 (en) Inhibition of biofilm formation
GB0403286D0 (en) Shower protected airer
GB0400043D0 (en) Shower protected airer
GB0419432D0 (en) Shower protected airer
GB0412138D0 (en) Definition of zeroclick
ZA200900104B (en) NF-KB inhibitor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070207

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

R17D Deferred search report published (corrected)

Effective date: 20070308

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/44 20060101ALI20070410BHEP

Ipc: A01N 43/42 20060101AFI20070410BHEP

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20100504

17Q First examination report despatched

Effective date: 20110624

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/19 20060101ALI20141023BHEP

Ipc: A61K 31/17 20060101AFI20141023BHEP

Ipc: A61K 31/435 20060101ALI20141023BHEP

Ipc: G01N 33/50 20060101ALI20141023BHEP

Ipc: A61K 38/17 20060101ALI20141023BHEP

18D Application deemed to be withdrawn

Effective date: 20140429

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

R18D Application deemed to be withdrawn (corrected)

Effective date: 20150429